ACC-001

9 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

Ongoing

Recruiting

Completed

Sites

139

Countries

Endpoints

162

Composite endpoints

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 162 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 2

Trials by status

Completed

Terminated

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Other (unclassified)

Global cognition

Memory

Neuroimaging

Safety / tolerability / PK

Function / daily living

Executive function / language

Behavior / neuropsychiatric

Tau biomarkers

Fluid / digital biomarkers

Amyloid biomarkers

Caregiver / quality of life

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 24 of 162 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

ADAS-CogCognition

Mini-Mental State Examination (MMSE)Cognition

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

Neuropsychiatric Inventory (NPI)Behavior

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

⌘K

9 of 9

Alzheimer’s disease and related dementias trials
	Asset / Disease area	Key I/E criterion						Evidence
NCT01227564Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease	ACC-001 Alzheimer’s disease	Alzheimer's disease	Ph 2	Completed	40	Feb 2014	1	results
NCT00960531A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease	ACC-001 Alzheimer’s disease	Alzheimer's disease	Ph 2	Terminated	28	Dec 2013	-	results
NCT00498602Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease	ACC-001 Alzheimer’s disease	mild-to-moderate AD	Ph 2	Completed	27	Feb 2013	1	results
ACCTIONAmyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease	ACC-001 Alzheimer’s disease	Alzheimer's disease	Ph 2	Completed	25	Jan 2014	1
NCT00479557Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease	ACC-001 Alzheimer’s disease	Alzheimer's disease	Ph 2	Completed	24	Jan 2013	1	results
NCT00955409Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease	ACC-001 Alzheimer’s disease	Alzheimer's disease	Ph 2	Completed	17	Dec 2013	-	results
NCT01238991Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease	ACC-001 Alzheimer’s disease	Alzheimer's disease	Ph 2	Terminated	11	Dec 2013	-	results
NCT00752232Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease	ACC-001 Alzheimer’s disease	mild-to-moderate AD	Ph 2	Completed	10	Jul 2012	1	results
NCT00959192Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease	ACC-001 Alzheimer’s disease	mild-to-moderate AD	Ph 2	Completed	9	Jan 2013	1	results

Showing 1-9 of 9 trials